Document Detail

Carbamazepine to treat primary nocturnal enuresis: double-blind study.
MedLine Citation:
PMID:  10657288     Owner:  NLM     Status:  MEDLINE    
Carbamazepine is chemically related to imipramine. It can reduce prostaglandin E2-like activity in inflammation. It caused overflow urinary incontinence, increased bladder capacity, sensitized renal tubules to antidiuretic hormone and leading to antidiuresis. This encouraged to use carbamazepine to treat primary enuresis. Twenty-six patients of either sex with a history of enuresis from birth were included in study. Their age ranged between 7 and 15 years (mean 9.3 years). They were assessed by history, physical examination, blood glucose, renal function tests, intravenous urogram and videocystourethrography. 30 days drug-free observation was performed to establish baseline voiding pattern. This was followed by two, 30 day treatment periods of either placebo or carbamazepine (200 mg) tablets, in a randomized, double-blind cross-over design. There was one week washout period between medications. The patients or their parents received calendar sheet to record wet and dry nights and offered subjective opinions concerning changes in sleep patterns, occurrence of nocturia and appearance of side-effects. A tablet was given to each patient before retiring. Those patients who showed no response to carbamazepine and placebo would be treated with 100 mg of indomethacin suppositories. The results show that of 26 patients 20 had 7 to 30 of 30 dry nights with carbamazepine, while 6 had 0 to 5 of 30 dry nights. The latter 6 patients reacted in the same manner with placebo, 4 of them showed better response with use of indomethacin. Six patients had 10 to 15 of 30 dry nights during placebo therapy and 20 had 0 to 6 of 30 dry nights. The mean number of dry nights was 3.92 +/- 5.22 with placebo and was 18.8 +/- 8.82 with carbamazepine. The difference in response to placebo and carbamazepine was statistically significant (p < 0.001). All the patients who responded sufficiently to indomethacin slept until the morning. No side effect was noticed with either treatment and repeated serum electrolytes and other laboratory tests were normal after treatment. It might be concluded that carbamazepine is useful for treatment of primary nocturnal enuresis.
N S Al-Waili
Related Documents :
15516268 - Pudendal nerve decompression in perineology: a case series.
9609638 - Late effects after radiotherapy for prostate cancer in a randomized dose-response study...
24015698 - Acute effect on satiety, resting energy expenditure, respiratory quotient, glucagon-lik...
12549638 - Long-term safety of extended-release oxybutynin chloride in a community-dwelling popula...
25155368 - Assessing the burden of illness from cervical dystonia using the toronto western spasmo...
8671108 - Treatments for postherpetic neuralgia--a systematic review of randomized controlled tri...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  European journal of medical research     Volume:  5     ISSN:  0949-2321     ISO Abbreviation:  Eur. J. Med. Res.     Publication Date:  2000 Jan 
Date Detail:
Created Date:  2000-02-17     Completed Date:  2000-02-17     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  9517857     Medline TA:  Eur J Med Res     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  40-4     Citation Subset:  IM    
Dubai Medical Center for Treatment and Research, P.O.Box 19964, Dubai, United Arab Emirates.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Carbamazepine / adverse effects,  therapeutic use*
Cross-Over Studies
Double-Blind Method
Enuresis / drug therapy*
Indomethacin / therapeutic use
Reg. No./Substance:
298-46-4/Carbamazepine; 53-86-1/Indomethacin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Is the amount of trabecular bone-loss dependent on bone mineral Density? A study performed by three ...
Next Document:  Adaptive recognition by nucleic acid aptamers.